Physiological barriers to drug delivery and selection for drug resistance limit survival outcomes 26 in cancer patients. In this study, we present preclinical evidence that a subtumoricidal 27 photodynamic priming (PDP) strategy can relieve drug delivery barriers in the tumor 28 microenvironment to safely widen the therapeutic window of a nanoformulated cytotoxic drug.
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Abstract 25
Physiological barriers to drug delivery and selection for drug resistance limit survival outcomes 26 in cancer patients. In this study, we present preclinical evidence that a subtumoricidal 27 photodynamic priming (PDP) strategy can relieve drug delivery barriers in the tumor 28 microenvironment to safely widen the therapeutic window of a nanoformulated cytotoxic drug. 29 In orthotopic xenograft models of pancreatic cancer, combining PDP with nanoliposomal 30 irinotecan (nal-IRI) prevented tumor relapse, reduce metastasis and increase both progression-31 free survival and 1-year disease-free survival. PDP enabled these durable improvements by 32 targeting multiple tumor compartments to (1) increase intratumoral drug accumulation by >10-33 fold, (2) increase the duration of drug exposure above a critical therapeutic threshold, and (3) 34 attenuate surges in CD44 and CXCR4 expression which mediate chemoresistance often observed 35 after multi-cycle chemotherapy. Overall, our results offer preclinical proof of concept for the 36 effectiveness of PDP to minimize risks of tumor relapse, progression and drug resistance and to 37 extend patient survival.
Introduction
40
Cancer is a constantly evolving disease that relies on both microenvironmental and 41 molecular compartments to resist and adapt to therapeutic insults(1). Significant efforts have been 42 invested in developing chemotherapeutics, biological agents, and cocktails to overcome resistance 43 mechanisms and escape pathways(2,3). However, these intense multimodal regimens have largely 44 been hindered by poor drug penetration into solid tumors(4), transient responses that fail to 45 eradicate aggressive populations with distinct molecular features(5), and significant off-target 46 toxicities associated with anti-cancer agents(6). 47 Here, we report a subtumoricidal photochemistry-based approach (hereafter referred to as 48 Photodynamic Priming, PDP) that primes multiple tumor compartments to enable more potent 49 and sustained anti-tumor activity of the FDA-approved nanoliposomal irinotecan (nal-IRI, also 50 known as MM-398, PEP02, BAX2398)(7). This unique photoinitiated approach offers multiple Author Manuscript Published OnlineFirst on DOI: 10.1158 /0008-5472.CAN-17-1700 5 PDAC is a devastating disease characterized by a dense fibrous stroma, that impedes drug 62 delivery, and by a profound resistance to standard chemotherapy(8). Therapeutic strategies 63 designed to ablate this tumor-associated desmoplasia yielded disappointing clinical results(9,10), 64 in part because PDAC-stroma interactions are extraordinarily complex and incompletely 65 understood(11). In 2015, nal-IRI combined with 5-fluorouracil and leucovorin was approved to 66 treat gemcitabine-refractory metastatic PDAC(12). Developed by Drummond and colleagues, 67 nal-IRI improves the circulation half-life, pharmacokinetics and intratumoral accumulation of 68 irinotecan and its active metabolite, SN-38, while minimizing toxic side effects(13). The superior 69 in vivo anti-cancer activity of nal-IRI, as compared to free irinotecan, is related to nal-IRI's 70 ability to extend the duration of intratumoral SN-38 above a critical threshold concentration. (14) 71 However, the high degree of variability in nal-IRI tumor deposition in vivo remains a challenge, 72 presumably due to the low permeability of liposomes within some tumors, as described 73 previously (14) . Moreover, because PDAC cells are highly resistant to standard chemotherapy(8), 74 it is increasingly evident that intensive chemotherapeutic regimens based on the maximum 75 tolerated dose can impose selection pressures that reveal residual populations of intrinsic or 76 acquired resistant clones, portending a poor outcome (15, 16) . Prime examples of highly 77 aggressive PDAC subpopulations include cells that overexpress hyaluronan receptor (CD44) and 78 C-X-C chemokine receptor type 4 (CXCR4) (17) (18) (19) . These markers play pivotal roles in self-79 renewal, multi-lineage differentiation, chemoresistance, potent proliferative and metastatic 80 capacity of PDAC, and correlate with poor prognosis in patients (17) (18) (19) . Previous studies have 81 shown that the front-line chemotherapy for PDAC, gemcitabine, induces a significant increase in 82 CD44 (17.5-fold) and CXCR4 (20-fold) protein levels in PDAC cell lines (16, 20) , and enriches 83 CD44+ cell population by ~40% in patient-derived xenografts and patient samples of PDAC(21). CAN-17-1700 followed by 10s vortexing and placing at −80°C for 1 hour. The samples were centrifuged at 176 10,000rpm for 10 minutes at room temperature and supernatants collected for HPLC analysis 177 (Dionex). The samples and standards (irinotecan and SN-38) were analyzed using a C18 reverse 178 phase column (Synergi Polar-RP 80A 250×4.60 mm 4μm column). The drug metabolites were 179 eluted running a gradient from 30% acetonitrile; 70% 0.1% TFA/H 2 O to 68% acetonitrile; 32% 180 0.1% TFA/H2O during a 13 minutes span at a flow rate of 1.0mL/min. The initial elute 181 composition was restored after 14 minutes and continued for 6 minutes before the next injection.
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The irinotecan peak was detected at ~7.7 minutes and the SN-38 peak eluted at ~8.4 minutes, 183 using an in-line fluorescence detector excited at 372nm and emitting at 556nm.
184
Tumor vasculature and Dil5-nal-IRI fluorescence imaging. 
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Irinotecan is a camptothecin prodrug that is converted by carboxylesterases to produce 276 the active SN-38 (7-ethyl-10-hydroxycamptothecin) metabolite, which is approximately 100 to 277 1000-fold more potent(27). The tumoral irinotecan and SN-38 pharmacokinetic profiles of nal-
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IRI were evaluated with and without PDP (Fig.2D,E) . In the orthotopic MIA PaCa-2 model, (Fig.2D) . In 281 contrast, following PDP+nal-IRI, intratumoral irinotecan levels were 11-fold higher (3.5%ID/g) 
15
and remained above 1%ID/g for 72 hours (Fig.2D) (Fig.2E) . PDP did not alter tumor carboxylesterase activity 286 (Fig.2F) , as a result the time-dependent change in the molar ratio of irinotecan-to-SN-38 in 287 tumors treated with nal-IRI was similar to the 'PDP+nal-IRI' group (Fig.2G) . observed in 'no-treatment' and 'PDP' over this same period (Fig.3B-D 
Author Manuscript Published OnlineFirst on November 29, 2017; DOI: 10.1158/0008-5472. CAN-17-1700 implantation, the mean tumor volume reduction in mice treated with 'nal-IRI' and 'PDP+nal-306 IRI' was 89% and 96%, respectively, compared to 'no-treatment' animals ( Fig.3C) . However, 307 shortly after termination of treatment and up to 120 days following implantation, animals treated 308 with 'nal-IRI' experienced a rapid tumor regrowth at a specific growth rate (SGR) of 309 4.80.3%/day, which is significantly higher than the 2.60.2%/day SGR in 'no-treatment' 310 (P<0.05; Fig.3E ). In contrast, 'PDP+nal-IRI' not only significantly inhibited tumor volume 311 growth by 96% by day 32 (with a SGR of -4.71%/day) (Fig.3D) , but also continued to suppress 312 tumor growth at an SGR of 1.70.9%/day for a prolonged period of up to 120 days (Fig.3E) . The 313 effect of 'PDP+nal-IRI' on tumor growth inhibition was found to be highly synergistic compared 314 to monotherapies (P=0.0041; Fig.S1 ). Furthermore, mouse body weight was longitudinally 315 monitored before and after treatment as a metric of toxicity (Fig.S2) . In 'PDP+nal-IRI' animals, AsPC-1 cells derived from a metastatic lesion (Fig.3F-I ). In agreement with the literature, AsPC- (Fig.4D,E) , the 346 expression of CD44 and CXCR4 were ~2 folds higher in the nal-IRI treated tumors compared to 347 the 'no-treatment' and 'PDP alone' groups. In contrast, 'PDP+nal-IRI' was able to maintain 348 CD44 and CXCR4 expressions at a baseline level despite tumor growth after treatment. Tumoral 349 CD44+, CXCR4+, and CD44+/CXCR4+ cell populations were evaluated by 350 immunofluorescence double staining at days 60 day 120 (Fig.4F) . At day 120 (Fig.4G) that nal-IRI treated tumors exhibited the highest level of E-cadherin expression (Fig.4H,I ) 356 relative to all other groups. However, at day 120, 'no-treatment', 'PDP', and 'nal-IRI' tumors 357 exhibited a complete loss of E-Cadherin expression, whereas a strong expression of E-Cadherin 22,000-fold, as compared to the 'no-treatment' group (Fig.5B,C) . Subtumoricidal PDP alone did 375 not significantly reduce the metastatic burden, compared to the 'no-treatment' (Fig.5B,C) . These 376 results suggest that the metastatic disease is primarily and effectively controlled by 'nal-IRI' at 377 early time points. At day 60, both 'nal-IRI' and 'PDP+nal-IRI' completely inhibited liver 378 metastasis and significantly reduced distant organ (lung, diaphragm, lymph node) metastases to 379 less than 50 cancer cells, compared to 'no-treatment' mice (>1 million cancer cells at lung, 380 diaphragm, lymph node) (Fig.5D) . Importantly, the benefit in controlling metastases provided by 381 nal-IRI alone over 60 days was lost by day 120. Only 'PDP+nal-IRI' achieved a significant 382 reduction in the overall and distant organ metastases by an average of ~16,000-fold and ~40,000-383 fold (P<0.01), respectively, compared to 'no-treatment' (Fig.5D ). In contrast, metastatic burden 384 in 'nal-IRI' group was not significantly different from 'no-treatment' mice at day 120 (Fig.5D) . 385 In addition to metastatic burden, the incidence of metastases in MIA PaCa-2 mouse model was 386 monitored at days 60 and 120. At day 60 (when diaphragm metastases were observed in 100% of 387 animals), 'PDP+nal-IRI' significantly reduced the incidence of diaphragm metastases by 66%, 388 while 'nal-IRI' did not reduce the incidence of metastasis (Fig.5E) . Consistent with the 389 metastatic burden data, by day 120, the incidence of liver, lung, and lymph node metastases in 390 the 'PDP+nal-IRI' mice was dramatically reduced to 6.7% and 33%, respectively, in contrast to 391 the high incidence of liver and distant metastases (60-100%) for the 'no-treatment', 'PDP', and 392 'nal-IRI' groups (Fig.5E) . DOI: 10.1158 /0008-5472.CAN-17-1700 20 in metastasis control provided by 'PDP+nal-IRI' translated to durable survival enhancement.
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Using moribundity as the endpoint (Fig.6A) , the orthotopic models of MIA PaCa-2 and 399 AsPC-1 cells demonstrated median survival times of 146 days (4.9 months) and 82.5 days 400 (2.75 months), respectively (Fig.6B-D (Fig.S1 ), no survival benefit was observed (Fig.S4) . (Fig.6E) summarizes the hazard ratio data across multiple variables. Here, the 423 hazard ratio is defined as the ratio of the probability of death in the treatment arm to the 424 probability in the no-treatment arm, and represents the instantaneous risk over the study (Fig.S5) . 
